Image Source: Pixabay

The 5 constituents in the munKNEE Psychedelic Compound-Based Drug Stocks Index were UP 3.4%, on average, last week and below is how each constituent stock performed, in descending order, and YTD, plus any recent news, commentary, and/or analysis on each company:

1. Mind Medicine (MNMD): UP 55.7% last week; UP 165.0% YTD
   • is primarily focused on the use of LSD and MNMA. Go here for much more extensive information on LSD and here for much more extensive information on MNMA.
   • Latest News, Commentary and/or Analysis:
     • MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder
2. Atai Life Sciences (ATAI): DOWN 1.4% last week; UP 48.9% YTD
   • is focused on the use of ketamine, DMT and ibogaine.  Go here for much more extensive information on Ketamine and here for much more extensive information on DMT.
   • Latest News, Commentary and/or Analysis:
   • atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01
3. GH Research (GHRS): DOWN 4.6% last week; UP 39.8% YTD
   • is primarily focused on the use of mebufotenin, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine.
   • Latest News, Commentary and/or Analysis:
     • GH Research Reports Full Year 2023 Financial Results and Provides Business Updates
4. Compass Pathways (CMPS): DOWN 5.2% last week; UP 24.3% YTD
   • is focused on the use of psilocybin (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin.
   • Latest News, Commentary and/or Analysis:
     • Compass Pathways Announces Q4 2023 Financial Results and Business Highlights
5. Incannex Healthcare (IXHL): DOWN 23.9% last week; DOWN 10.1% YTD
   • is researching and developing therapies and products with the world's largest portfolio of medicinal cannabinoid and psychedelic pharmaceutical products.
   • Latest News, Commentary and/or Analysis: None

Summary

The munKNEE Psychedelic compound-Based Drug Stocks Index went UP 3.4% last week and is now UP 44.1% YTD.

More By This Author:

Our 7 Largest Cannabis MSO Stocks Dropped 7.1% Last Week
Cannabis Company Green Thumb Has Bounced Back From A Rocky Q4
Q4 Results Of Cannabis Company Verano Holdings Were Down Across The Board